

1 **Gene expression based molecular test proves clinical validity as diagnostic aid for the**
2 **differential diagnosis of psoriasis and eczema in formalin fixed and paraffin embedded**
3 **tissue**

4

5 **Authors:**

6 Felix Fischer¹, Sophie Roenneberg², Larissa Graner⁴, Franziska Schlenker⁴, Roland
7 Zengerle^{3,4}, Fabian J. Theis^{1,6}, Carsten B. Schmidt-Weber⁵, Tilo Biedermann², Felix Lauffer²,
8 Natalie Garzorz-Stark² and Stefanie Eyerich^{5,*}

9

10 **Affiliations:**

11 ¹Institute of Computational Biology, Helmholtz Center Munich, Neuherberg, Germany

12 ²Department of Dermatology and Allergy, Technical University of Munich, Munich,
13 Germany

14 ³Laboratory for MEMS Applications, Department of Microsystems Engineering - IMTEK,

15 ⁴University of Freiburg, Freiburg, Germany, Hahn-Schickard Society for Applied Research,
16 Freiburg, Germany

17 ⁵ZAUM – Center of Allergy and Environment, Technical University of Munich and
18 Helmholtz Center Munich, Member of the German Center for Lung Research (DZL), Munich,
19 Germany

20 ⁶Department of Mathematics, Technical University of Munich, Garching, Germany

21 *To whom correspondence should be addressed: stefanie.eyerich@tum.de

22

23

24

25 **Abstract**

26

27 Highly specific and efficient drugs have been developed during the last two decades to treat
 28 non-communicable chronic inflammatory skin diseases (ncISD). Due to their specificity,
 29 these drugs are asking for precise diagnostic measures to attribute the most efficient treatment
 30 to each patient. Diagnosis, however, is complicated by the complex pathogenesis of ncISD
 31 and their clinical and histological overlap. Especially, precise diagnosis of psoriasis and
 32 eczema is difficult in special cases and molecular diagnostic tools need to be developed to
 33 support gold standard diagnosis of patients. In this line, we have developed a real-time based
 34 molecular classifier to distinguish psoriasis from eczema in RNA-later fixed skin samples.
 35 However, this type of skin sample is not regularly used in routine diagnostics. Therefore, we
 36 evaluated if the combination of *NOS2* and *CCL27* expression in lesional skin can be
 37 transferred to formalin-fixed paraffin embedded (FFPE) tissue. We present a FFPE-based
 38 molecular classifier (MC) that determines the probability for psoriasis with a specificity and
 39 sensitivity of 100% and 92%, respectively, and an area under the curve (AUC) of 0.97
 40 delivering comparable results to the RNA-later based MC. The probability for psoriasis as
 41 well as the PCR result of *NOS2* expression correlated positive with disease hallmarks of
 42 psoriasis and negative with eczema hallmarks. This tool now offers broad usage in pathology
 43 laboratories and can support diagnostic decision making on a molecular level.

44

45 **Key Words**

46 Diagnostic aid; FFPE, *NOS2*; *CCL27*; inflammatory skin diseases; precision medicine

47

48

49 **Introduction**

50

51 Psoriasis and eczema are one of the most prevalent and relevant skin diseases worldwide with
 52 an incidence rate for both diseases together of at least 2,000/100,000 (Bylund, von
 53 Kobyletzki, Svalstedt, & Svensson, 2020; Thyssen, Johansen, Linneberg, & Menne, 2010;
 54 Vena et al., 2010). Although more than a dozen of specific immune-modulating therapies
 55 including biologicals and small molecules have been made available to treat patients more
 56 efficiently than ever before over the last decade (Tizek et al., 2021), the ultimate breakthrough
 57 has yet to arise due to missing accurate diagnostics tools. Diagnosis of both diseases largely
 58 depends on a subjective visual exam and histopathological examination. Due to phenotypical
 59 overlaps of both diseases up to 50 % of cases are misdiagnosed (Kolesnik, Franke, Lux,
 60 Quist, & Gollnick, 2018). To close this important diagnostic gap, a gene expression based
 61 classifier using *NOS2* and *CCL27* as marker genes has been proposed and its clinical validity
 62 has been examined and proven in various patient cohorts (Bentz et al., 2021; Brunner et al.,
 63 2018; Garzorz-Stark et al., 2016; Quaranta et al., 2014; Stoffel et al., 2018). Renert-Yuval et
 64 al. list the *NOS/CCL27* classifier as the only accepted disease classifier for psoriasis and
 65 eczema (Renert-Yuval et al., 2021). Here, we applied the molecular classifier in formalin-
 66 fixed paraffin embedded biopsy specimens of eczema and psoriasis to validate its clinical
 67 utility as diagnostic aid in pathology laboratories (n=107). We demonstrated that the FFPE-
 68 based classifier delivered the correct clinical and histopathological diagnosis on the level of
 69 RT-PCR with a test sensitivity and specificity of 92% and 100%, respectively. By opening
 70 FFPE samples to molecular diagnostics, this FFPE-based classifier can now be used in routine
 71 diagnostics and aid physician in their diagnostic decision making.

72

73

74 **Material and Methods**

75

76 *Patients and material sampling*

77 FFPE samples for this retrospective study were derived from the Biobank Biederstein and
 78 consisted of 107 patients (psoriasis, n=27; eczema, n=48, disease subtypes, n=18 and cases
 79 with contradictory diagnosis n=14)). Final diagnosis of patients was determined by at least
 80 two dermatologists taking a comprehensive view onto the clinical picture, family history,
 81 laboratory parameters and histological assessment. Characteristics of all patients are shown in
 82 Table 1. Patients treated with immune-efficient medication prior to material sampling were
 83 excluded from the study. The study was approved by the local ethical committee (project
 84 number 2773/10 and 515/17). Generated data and codes can be provided upon request.

85

86 *Characteristics of FFPE tissue and isolation of total RNA*

87 Skin biopsies (Ø3-6mm) from patients with a potential diagnosis of psoriasis or eczema were
 88 taken under local anesthesia by a dermatologist and immediately fixed in neutral buffered
 89 formalin for 8-48 hours at room temperature or 4°C. Fixed biopsies were paraffin embedded
 90 according to standard procedures (one biopsy per paraffin cassette). Unstained FFPE skin
 91 biopsies (<10 years of age) were used to isolate mRNA. Here, tissue sections with a thickness
 92 of 10 µm were generated from each FFPE skin sample. The first sections containing both
 93 epidermis and dermis were trimmed (at least 30µM) and discarded to avoid usage of degraded
 94 material. mRNA was extracted from in total three FFPE sections using a magnetic bead-based

95 purification method according to the manufacturer's protocol (InnuPREP MP Basic FFPE
96 RNA Kit, IST Innuscreen, Germany). The mRNA eluates were analyzed immediately after
97 the extraction by real-time PCR using specific primer and hydrolysis probes.

98

99 *Primer design and Real-time PCR*

100 For specific amplification of the genes of interests *NOS2* and *CCL27* as well as of the
101 reference genes, *TBP* and *SDHAF2*, primers and hydrolysis probes were designed using the
102 primer design tool PrimerBLAST from NCBI ([https://www.ncbi.nlm.nih.gov/tools/primer-](https://www.ncbi.nlm.nih.gov/tools/primer-blast/)
103 [blast/](https://www.ncbi.nlm.nih.gov/tools/primer-blast/)). Oligonucleotides were synthesized by biomers (Germany). Probes were labeled with
104 an Atto 647N fluorophore at the 5'-end and quenched with a BHQ2 quencher at the 3'-end.

105 Primer and probe sequences were as follows (forward, reverse and probe): 5'-
106 TTCCTGGTTTGACTGTCCTTACC-3', 5'- T7TTCACGTGTGGGGCTTGC-3' and 5'-
107 CGGGGAGGCAGTGCAGCCAGC-3' for *NOS2*; 5'- ACCCTACAGCAGCATTCCTAC-3',
108 5'- AGCTTGTCTGAGAGTGGCTTTC-3' and 5'-
109 ACCCAGCACTGCCTGCTGTACTCAGCTC-3' for *CCL27*; 5'-
110 ATGGATCAGAACAACAGCCTGC-3', 5'- CATTGGACTAAAGATAGGGATTCCG-3'
111 and 5'-TCAGGGCTTGGCCTCCCCTCAGGGTGCC-3' for *TBP*; 5'-
112 CGGTGTCTACAGTGTCTCGAC-3', 5'- GATGTCACACTGAGCAAAGGAG-3' and 5'-
113 CGCTGATGCTTGCTCTGTCAAGGCACAGCC-3' for *SDHAF2*.

114 Real-time PCR reactions were carried out in 96-well plates using a Thermo Fisher Scientific
115 one-step RT-PCR master mix. Thermocycling and fluorescence detection were performed in a
116 qTower³ (Analytik Jena, Germany) and amplification results were analyzed using the
117 qPCRsoft 4.1 software (Analytik Jena).

118

FFPE-based molecular classifier (MC) built-up

The molecular classifier was built using L2 regularized logistic regression. The molecular classifier predicts the disease state (probability for psoriasis) directly from the normalized CT values of *NOS2* and *CCL27* normalized to the reference genes *SDHAF2* and *TBP*. For classification the psoriasis and eczema subtypes are aggregated to their respective high level labels (eczema or psoriasis). The model was calculated using LinearRegression implementation from scikit-learn with an L2 regularization strength of 100. In addition, the uncertainty of the model is estimated based on the predicted probability (cases with a predicted probability between 45% and 55% are predicted as undetermined). The model was trained on 77 patients with a clear diagnosis of psoriasis and eczema (atopic dermatitis (AD) and nummular eczema (NE)) and achieved an AUC of 0.97 +/- 0.06 on the training data. Furthermore, the model achieved a sensitivity = 91% and a specificity = 91% on the evaluation set which includes the training data plus 18 additional patients with prediagnosed subtypes of psoriasis and eczema.

Correlation of FFPE-based MC probability and PCR results with clinical attributes

Pearson correlation coefficients were calculated to determine the correlation between the FFPE-based MC determined probabilities for psoriasis, the negative delta CT PCR results of *CCL27* and *NOS2* as well as histological parameters, morphology of the lesion, comorbidities, laboratory parameters and family history.

Results

The FFPE-based molecular classifier (MC) precisely separates eczema from psoriasis and efficiently identifies subtypes of both diseases

To evaluate the potential of FFPE samples for molecular diagnostics, 76 FFPE samples of lesional psoriasis (n=27) and eczema (atopic dermatitis n=28; nummular eczema n=21) were analyzed by probe-based real-time PCR for the expression of *NOS2* and *CCL27*. To calculate a FFPE-based molecular classifier (MC) for differentiation of psoriasis and eczema, a logistic regression model was fitted with a 5-times cross validation. This classifier was designed to predict the probability of psoriasis with a cut-off value of 55% (The range between 45% and 55% would no probability (undetermined). Test specificity for psoriasis was 100% with a sensitivity of 92% and an area under the ROC curve (AUC) of 0.97 +/- 0.06 (Fig. 1A). Two psoriasis patients were mis-classified, and two further psoriasis patients reached a probability between 45-55% and thereby could not be evaluated (Fig. 1B). In a next step, we used the FFPE-based MC to classify subtypes of psoriasis (psoriasis guttata n=5; psoriasis palmoplantaris n=1; generalized pustular psoriasis n=2; and psoriasis pustulosa palmoplantaris n=3) and eczema (dishidrotic eczema n=4; hyperkeratotic rhagadiforme eczema n=3) (Fig. 1B). Whereas all cases of psoriasis guttata, psoriasis palmoplantaris and psoriasis pustulosa pampoplantaris were diagnosed correctly by the FFPE-based MC, cases of dishidrotic and hyperkeratotic-rhagadiform eczema as well as generalized pustular psoriasis tended to be misdiagnosed.

FFPE classifier results correlate with clinical attributes of psoriasis and eczema

To understand if the determined probability for psoriasis also correlates with clinical attributes associated with psoriasis or eczema, Person correlation coefficients were

determined (Fig. 2). The probability of psoriasis highly and positively correlated with the histological attributes 'dilated dermal capillaries' ($r=0.61$), 'acanthosis' ($r=0.51$), 'neutrophils' ($r=0.39$) and 'parakeratosis' ($r=0.33$) (Fig. 2) – all hallmarks for the pathogenesis of psoriasis. This positive correlation was followed by a positive correlation of negative CT values of *NOS2* ($r=0.43$; $r=0.33$; $r=0.23$; $r=0.25$, respectively) and a negative correlation with negative delta CT values for *CCL27* ($r=-0.54$; $r=-0.5$; $r=-0.48$; $r=-0.22$, respectively). In line, the probability of psoriasis and the negative delta CT for *NOS2* correlated positive with a psoriasis type morphology ($r=0.77$ and $r=0.56$) and arthritis ($r=0.34$ and $r=0.35$), whereas a negative correlation was determined for an eczema type morphology ($r=-0.77$ and $r=-0.56$) and rhinoconjunctivitis allergica (RCA) ($r=-0.47$ and $r=-0.28$) (Fig. 2). The probability of psoriasis also correlated positive with the therapeutic efficiency of IL12/IL-23 ($r=0.99$) and TNF- α inhibition ($r=0.56$), however negative with the response to Fumarate ($r=-0.34$) of IL-17 inhibition ($r=-0.74$). No correlations of the laboratory parameters 'Stap.aureus' and specific 'IgE' as well as the family history of for psoriasis and eczema were identified.

The FFPE-based MC supports diagnostic decision making in patients with inconsistent diagnosis

To further evaluate the potential of the FFPE-based MC to support diagnostic decision making, 14 patient samples with discrepant clinical and histological diagnosis were analyzed. Within this cohort, 9 patients were assigned a probability for psoriasis and 5 patients were classified as eczema (Fig. 3A). Patient 43, a close to 80 year old woman, developed shortly after a respiratory infection itchy, pustular reddening overall the whole body. Bacterial or viral infections were not detected. Extensive lesional skin at the thigh and knee were surgically excised. Histologically, the lesions presented with infiltration of neutrophils and isolated eosinophils, signs of spongiosis and in part parakeratosis. The patient was diagnosed

with psoriasis pustulosa, however, acute generalized exanthematic pustulosis (AGEP) could not be ruled out. In fact, psoriasis pustulosa and AGEP can hardly be distinguished by classical histological examination. Our FFPE-based MC assigned this patient a probability of psoriasis of 74.49%. After initiation of Ixekizumab, the skin status of this patient improved supporting the MC-based classification (Fig. 3B).

Patient 59, a mid-sixty male, presented in the clinic with reddish, hyperkeratotic, scaly and itchy skin lesions at both palmae accompanied by erythematous, heavily infiltrated plaques at the back, the capillitium and retroauricular. Histopathological examination showed psoriasiform acanthosis, hyperparakeratosis, a lymphocytic infiltrate and isolated plasma cells leading to the diagnosis of psoriasiform perivascular dermatitis, while clinically diagnostics was in favor for psoriasis. The FFPE-based MC assigned a probability for psoriasis of 99.53%. Skin lesions at the palms and body cleared after 6 months of methothrexate therapy (Fig. 3B).

Patient 62, a male at the end of his sixties, presented at the clinic with confluent, erythematous, crude-lamellar, scaly plaques at both palmae. Histologically, extended hyperparakeratosis, serum crusts, psoriasiforme epidermis hyperplasia combined with spongiosis and a linear lymphocytic infiltrate in absence of neutrophils and eosinophils was described leading to the diagnosis of hyperkeratotic, in part dyshidrotic hand eczema. The FFPE-based MC assigned this patient a probability for psoriasis of 8.25% and thereby a high likelihood of an underlying eczematous disease. Treatment with a topical corticosteroids and altitretinoin improved the skin lesions supporting the MC-based classification (Fig. 3B).

Patient 75, a woman at beginning of her sixties, has been suffering for years under recurrent itchy, sharply demarcated erythematous plaques, with in part lamellar scales and excoriations as clinically seen in both psoriasis and eczema variants. Histologically, a psoriasiform hyperplasia of the epidermis combined with hyperparakeratosis, hypogranulosis, elongated rete-ridges, papillomatosis and focal spongiosis in upper epidermis layers was found. A

214 perivascular dense lymphocytic infiltrate with absence of neutrophils and eosinophils was
215 identified. The patient was diagnosed with a nummular eczema. This is supported also by the
216 FFPE-based MC that assigned a probability of 18.29% to this patient (Fig. 3B) and skin
217 lesions improved with topical corticosteroids and UVB phototherapy.

218

219

220

Discussion

The development of highly specific biologic drugs has revolutionized treatment options for various diseases during the past two decades (Noda, Krueger, & Guttman-Yassky, 2015). However, due to their specificity, these drugs are most efficient in only a small group of diseases and patients calling for efficient diagnosis and subsequent assignment of each patient to the most appropriate drug. Whereas molecular diagnostics have been already developed and used for cancer diagnosis followed by decision making on treatment regimens, they are not well established in the field of chronic inflammatory skin diseases, yet (Grazia, Penna, Perotti, Anichini, & Tassi, 2014; Levine & Fisher, 2014; Usher-Smith, Emery, Kassianos, & Walter, 2014). In previous work, we have developed a disease classifier to dissect psoriasis from eczema based on the expression levels of *NOS2* and *CCL27* (Quaranta et al., 2014; Garzorz-Stark et al., 2016). This classifier has been validated by several groups and found its acceptance in the field (Bentz et al., 2021; Brunner et al., 2018; Stoffel et al., 2018). However, it was established on RNA-later fixed skin that is regularly used in research, but not in clinics, private practices and pathology laboratories. Within these institutions, skin samples usually are formalin fixed and paraffin embedded (FFPE). This way of fixation allows long-term storage of samples and optimal assessment of histological hallmarks, however, by cross-linking of proteins with RNA and RNA degradation due to the fixation procedure, RNA isolation from FFPE samples can be challenging. Here, optimized protocols have been developed to minimize side effects of the fixation method and now allow to use this sample type for efficient diagnostics. Within this work, we have transferred the RNA-later molecular classifier to FFPE samples and were able to retrieve comparable results. Whereas the RNA-later based MC dissected psoriasis from eczema with a specificity and sensitivity for psoriasis of 100% and 97.7%, respectively and an AUC of 0.99, the FFPE-based classifier determined probabilities for psoriasis with a specificity and sensitivity of 100% and 92%, respectively, and an AUC of 0.97 (Garzorz-Stark et al., 2016). Whereas only two classical psoriasis

samples were not classified correctly by the FFPE-based MC, all atopic dermatitis and nummular eczema cases were diagnosed precisely. The FFPE-based MC was also able to predict the diagnosis of psoriasis subtypes, however, delivered conflicting results for dyshidrotic and hyperkeratotic-rhagadiform eczema. Unfortunately, the cohort of these subtypes was very small (4 and 3 cases, respectively) and data on treatment regimens and therapeutic efficiency were not available. As these patients are difficult to diagnose by gold standard diagnostics, further studies need to be undertaken to prove the efficiency of molecular classification in this eczema subtype. In addition, and in line with previous findings, the FFPE-based classifier probability highly correlated with disease hallmarks of psoriasis, but not hallmarks of eczema (Garzorz-Stark et al., 2016). Therefore, the reliability of the two markers, *NOS2* and *CCL27*, has been shown now also in a FFPE tissue arguing for implementation of this molecular diagnostic aid in clinical routine diagnostics and pathology laboratories. Here, however, further efforts have to be undertaken to simplify and speed up the labor- and cost-intensive purification of RNA from FFPE tissue. In addition, fully automated systems need to be developed to be integrated into the processes in routine diagnostic laboratories.

Acknowledgments

The authors thank Kerstin Weber for excellent technical support and the Biobank Biederstein for patient samples. This work was supported by the Medical Valley Award.

References

- Bentz, P., Eyerich, K., Weber, K., Kluge, L., Ofenloch, R., & Weisshaar, E. (2021). [Cohort study for long-term follow-up of patients in whom the so-called "molecular classifier" is used to distinguish eczema from psoriasis: Background and implementation]. *Hautarzt*, 72(4), 354-357. doi:10.1007/s00105-021-04774-9
- Brunner, P. M., Pavel, A. B., Khattri, S., Leonard, A., Malik, K., Rose, S., . . . Guttman-Yassky, E. (2018). Baseline IL22 expression in atopic dermatitis patients stratifies tissue responses to fezakinumab. *J Allergy Clin Immunol*. doi:10.1016/j.jaci.2018.07.028
- Bylund, S., von Kobyletzki, L. B., Svalstedt, M., & Svensson, A. (2020). Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. *Acta Derm Venereol*, 100(12), adv00160. doi:10.2340/00015555-3510
- Garzorz-Stark, N., Krause, L., Lauffer, F., Atenhan, A., Thomas, J., Stark, S. P., . . . Eyerich, K. (2016). A novel molecular disease classifier for psoriasis and eczema. *Exp Dermatol*, 25(10), 767-774. doi:10.1111/exd.13077
- Grazia, G., Penna, I., Perotti, V., Anichini, A., & Tassi, E. (2014). Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review). *Int J Oncol*, 45(3), 929-949. doi:10.3892/ijo.2014.2491
- Kolesnik, M., Franke, I., Lux, A., Quist, S. R., & Gollnick, H. P. (2018). Eczema in Psoriatico: An Important Differential Diagnosis Between Chronic Allergic Contact Dermatitis and Psoriasis in Palmoplantar Localization. *Acta Derm Venereol*, 98(1), 50-58. doi:10.2340/00015555-2779
- Levine, D., & Fisher, D. E. (2014). Current status of diagnostic and prognostic markers in melanoma. *Methods Mol Biol*, 1102, 177-197. doi:10.1007/978-1-62703-727-3_11
- Noda, S., Krueger, J. G., & Guttman-Yassky, E. (2015). The translational revolution and use of biologics in patients with inflammatory skin diseases. *J Allergy Clin Immunol*, 135(2), 324-336. doi:10.1016/j.jaci.2014.11.015

296 Quaranta, M., Knapp, B., Garzorz, N., Mattii, M., Pullabhatla, V., Pennino, D., . . . Eyerich, K. (2014).
 297 Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and
 298 eczema. *Sci Transl Med*, 6(244), 244ra290. doi:10.1126/scitranslmed.3008946

299 Renert-Yuval, Y., Thyssen, J. P., Bissonnette, R., Bieber, T., Kabashima, K., Hijnen, D., & Guttman-
 300 Yassky, E. (2021). Biomarkers in atopic dermatitis-a review on behalf of the International Eczema
 301 Council. *J Allergy Clin Immunol*, 147(4), 1174-1190 e1171. doi:10.1016/j.jaci.2021.01.013

302 Stoffel, E., Maier, H., Riedl, E., Bruggen, M. C., Reininger, B., Schaschinger, M., . . . Brunner, P. M.
 303 (2018). Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1
 304 activation with some distinct immunological characteristics. *Br J Dermatol*, 178(5), 1151-1162.
 305 doi:10.1111/bjd.16126

306 Thyssen, J. P., Johansen, J. D., Linneberg, A., & Menne, T. (2010). The epidemiology of hand eczema
 307 in the general population--prevalence and main findings. *Contact Dermatitis*, 62(2), 75-87.
 308 doi:10.1111/j.1600-0536.2009.01669.x

309 Tizek, L., Schuster, B., Gebhardt, C., Reich, K., von Kiedrowski, R., Biedermann, T., . . . Garzorz-
 310 Stark, N. (2021). Molecular diagnostics in dermatology: An online survey to study usage, obstacles
 311 and requirements in Germany. *J Dtsch Dermatol Ges*. doi:10.1111/ddg.14659

312 Usher-Smith, J. A., Emery, J., Kassianos, A. P., & Walter, F. M. (2014). Risk prediction models for
 313 melanoma: a systematic review. *Cancer Epidemiol Biomarkers Prev*, 23(8), 1450-1463.
 314 doi:10.1158/1055-9965.EPI-14-0295

315 Vena, G. A., Altomare, G., Ayala, F., Berardesca, E., Calzavara-Pinton, P., Chimenti, S., . . . Cricelli,
 316 C. (2010). Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational
 317 study from a national primary care database. *Eur J Dermatol*, 20(5), 593-598.
 318 doi:10.1684/ejd.2010.1017

319

320

Tables

	n	age		n	age
<i>psoriasis (pso) (n=27)</i>			<i>aopic dermatitis (n=28)</i>		
m	20	49.7±12.56	m	13	47.69±25.82
w	7	65.86±10.12	w	15	55.67±29.08
<i>psoriasis guttata (PG) (n=5)</i>			<i>nummular eczema (n=21)</i>		
m	2	36.5±5.5	m	10	62.6±15.32
w	3	40.23±3.86	w	11	72±14.25
<i>generalized pustular psoriasis (GPP) (n=2)</i>			<i>dishidrotic eczema (DHE) (n=4)</i>		
m	1	55-60	m	1	70-75
w	1	25-30	w	3	55.67±19.29
<i>psoriasis palmoplantaris (PP) (n=1)</i>			<i>hyperkeratotic-rhagadiiform eczema (HRE) (n=3)</i>		
w	1	40-45	m	1	60-65
<i>psoriasis pustulosa palmoplantaris (PPP) (n=3)</i>			w	2	70±21.21
m	2	42±9.9	<i>unclear cases (n=14)</i>		
w	1	45-50	m	8	56.86±13.36
			w	6	66±9.7

Table 1: Patient characteristics

Figures and figure legends




Figure 1: The FFPE-based Molecular classifier (MC) dissects clinically clear cases of psoriasis and eczema and is also efficient in subtypes of both diseases.

A) The molecular classifier (MC) was trained on clear cases of eczema (atopic dermatitis (AD n=28), nummular eczema (NE, n=21) and psoriasis (Pso, n=27) using a logistic regression model with a 5-fold cross validation delivering the probability of psoriasis. CT values of *NOS2* and *CCL27* were normalized to the reference genes *SDHAF2* and *TBP*. The graph indicates the dissection of eczema and psoriasis samples exemplarily for normalization B) FFPE-based MC determined probabilities for psoriasis in clear cases of atopic dermatitis (AD), nummular eczema (NE) and psoriasis (Pso). The grey are between 45%-55% indicates undetermined probabilities C) The FFPE-based MC was used to predict the probability for psoriasis in subtypes of eczema and psoriasis (dyshidrotic eczema, DHE n=; hyperkeratotic-rhagadiform eczema, HRE n=; psoriasis guttata, PG n=5; psoriasis palmoplantar, PP n=1; generalized pustular psoriasis, GPP n=2; and psoriasis pustulosa palmplantaris, PPP n=2). A probability between 45% and 55% was defined as not evaluable.

Fig. 2




Figure 2: The FFPE-based MC determined probability for psoriasis correlates with disease hallmarks. The probability for psoriasis as well as the negative delta CT values for CCL27 and NOS2 were correlated with clinical attributes by Pearson correlation.




Figure 3: The FFPE-based MC is able to support diagnosis of unclear cases.

A) The FFPE-based MC was applied on clinically and histologically challenging cases of patients with a suspected diagnosis of psoriasis or eczema and subtypes of both diseases (n=14). Given patient numbers represent numerical numbering and not biobank IDs. B) Clinical pictures and histological H&E stainings of selected patients that were assigned a probability of psoriasis by the FFPE-based MC.